Cost Curve News - News - https://www.costcurvenews.com/blog/page/5/

It’s Formulary Season, and Early Analyses Suggest Big Changes in How PBMs Approach Biosims

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

Cost Curve News

The FDA Assault on DTC Advertising Is Targeting a Lot More Than Just TV Ads

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

Cost Curve News

Payers Say COVID and Flu Vaccine Reimbursements Will Remain Solid, Regardless of CDC Changes

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

Cost Curve News

The Second-Day Reaction to the DTC Letters: Oprah Gets a Look, Pharma Gets Targeted, and FDA’s Capacity Gets Questioned

It’s a quick one today. I’m on the road, attending the Oliver Wyman Health Innovation Summit. I had the opportunity to share the stage yesterday with ICER’s Sarah Emond, and

2 months ago

Keep Reading

Cost Curve News

A Smart Tufts CEVR Look at Every Cost-Effectiveness Analysis Published for the Meds CMS Is Currently ‘Negotiating’

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

Cost Curve News

The UK Abandoned Biopharma Innovation. Now Biopharma Is Abandoning the UK

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

Cost Curve News

Was the White House’s Attack on DTC Advertising Fueled by Robots?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

Cost Curve News

340B Remains In the Spotlight, With New Legislation, Court Battles, and the Pending Rebate Model Launch

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

Cost Curve News

I’m Not Sure Where to Begin Today. Health Costs? 340B? DTC Ads? Patent Shenanigans?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

Cost Curve News

Hospitals Allege 340B Collusion in a Context-Free Letter to the DOJ and FTC

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

2 months ago

Keep Reading

It’s Formulary Season, and Early Analyses Suggest Big Changes in How PBMs Approach Biosims

The FDA Assault on DTC Advertising Is Targeting a Lot More Than Just TV Ads

Payers Say COVID and Flu Vaccine Reimbursements Will Remain Solid, Regardless of CDC Changes

The Second-Day Reaction to the DTC Letters: Oprah Gets a Look, Pharma Gets Targeted, and FDA’s Capacity Gets Questioned

A Smart Tufts CEVR Look at Every Cost-Effectiveness Analysis Published for the Meds CMS Is Currently ‘Negotiating’

The UK Abandoned Biopharma Innovation. Now Biopharma Is Abandoning the UK

Was the White House’s Attack on DTC Advertising Fueled by Robots?

340B Remains In the Spotlight, With New Legislation, Court Battles, and the Pending Rebate Model Launch

I’m Not Sure Where to Begin Today. Health Costs? 340B? DTC Ads? Patent Shenanigans?

Hospitals Allege 340B Collusion in a Context-Free Letter to the DOJ and FTC

Latest Posts

When Will CMS Publish the Next Set of ‘Negotiated’ Prices for Medicare?

Why a New Drug Just Entered the Market With a List Price One-Tenth of Its Rival

The Five Most Interesting Things Lilly’s Dave Ricks Said on the Cheeky Pint Pod

The Obesity Pricing Paradigm Gets Even More Complex With Novo’s $199 Wegovy Offer

CMS Is About to Announce ‘Negotiated’ Prices on 15 More Medicines. Here’s What the Companies Involved Have Said About Those Prices

Popular

When Will CMS Publish the Next Set of ‘Negotiated’ Prices for Medicare?

Why a New Drug Just Entered the Market With a List Price One-Tenth of Its Rival

The Five Most Interesting Things Lilly’s Dave Ricks Said on the Cheeky Pint Pod

The Obesity Pricing Paradigm Gets Even More Complex With Novo’s $199 Wegovy Offer

CMS Is About to Announce ‘Negotiated’ Prices on 15 More Medicines. Here’s What the Companies Involved Have Said About Those Prices

Coming Soon to a Pharmacy Near You: Big List Price Cuts on Blockbuster Drugs

Latest News

When Will CMS Publish the Next Set of ‘Negotiated’ Prices for Medicare?

Why a New Drug Just Entered the Market With a List Price One-Tenth of Its Rival

Subcribe To Newsletter